Advertisement

Pancreatic resections for benign intraductal papillary mucinous neoplasms: Collateral damages from friendly fire

      Abstract

      Background

      Surgical resection of intraductal papillary mucinous neoplasms is based on preoperative high-risk stigmata/worrisome features, but the risk of overtreatment remains high. The aim of this study was to evaluate surgical indications and perioperative and long-term complications in patients with low-grade intraductal papillary mucinous neoplasms.

      Methods

      Patients who underwent surgical resection between 2009 and 2018 with a final histology of low-grade intraductal papillary mucinous neoplasms were included. Surgical indications, type of surgery, and short- and long-term outcomes were evaluated.

      Results

      A significant decrease in the rate of patients resected for low-grade intraductal papillary mucinous neoplasms was observed (43.6% in 2009–2012 vs 27.8% in 2013–2018; P = .003), and 133 patients were finally included (62 women, median age: 68 years). Of these, 24.1% had 1 worrisome feature, 39.8% had ≥2 worrisome features, 18.8% had ≥1 high-risk stigmata, and 15.8% had ≥1 worrisome features + 1 high-risk stigmata. Overall surgical morbidity was 55.6%, 15.8% had Clavien-Dindo ≥3 complications, reoperation rate was 3.8%, and 90-day postoperative mortality was 1.5%. After a median follow-up of 60 months, 13 patients (11.5%) had a recurrence of benign intraductal papillary mucinous neoplasm in the pancreatic remnant, and 2 patients (1.8%) developed pancreatic ductal adenocarcinoma. After partial pancreatectomy, 51.3% of patients were taking pancreatic enzyme replacement therapy. Among nondiabetics, 26% developed diabetes after partial pancreatectomy, of which 38% were insulin-dependent. Eighteen patients (13.7%) developed incisional hernia.

      Conclusion

      Given the rates of morbidity and long-term complications after pancreatic resections, surgeons should attentively balance the true risks of intraductal papillary mucinous neoplasm degeneration with the risks of surgical resection in each patient.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ohashi K.
        • Murakami Y.
        • Muruayama M.
        • et al.
        Four cases of “mucin-producing” cancer of the pancreas on specific findings of the papilla of Vater.
        Prog Dig Endosc. 1982; 20: 348-351
        • Matsumoto T.
        • Aramaki M.
        • Yada K.
        • et al.
        Optimal management of the branch duct type intraductal papillary mucinous neoplasms of the pancreas.
        J Clin Gastroenterol. 2003; 36: 261-265
        • Sugiyama M.
        • Izumisato Y.
        • Abe N.
        • et al.
        Predictive factors for malignancy in intraductal papillary-mucinous tumours of the pancreas.
        Br J Surg. 2003; 90: 1244-1249
        • Tanaka M.
        • Chari S.
        • Adsay V.
        • et al.
        International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas.
        Pancreatology. 2006; 6: 17-32
        • Goh B.K.P.
        • Tan D.M.Y.
        • Ho M.M.F.
        • et al.
        Utility of the Sendai Consensus Guidelines for branch-duct intraductal papillary mucinous neoplasms: a systematic review.
        J Gastrointest Surg. 2014; 18: 1350-1357
        • Tanaka M.
        • Fernández-Del Castillo C.
        • Adsay V.
        • et al.
        International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas.
        Pancreatology. 2012; 12: 183-197
        • Tanaka M.
        • Fernández-del Castillo C.
        • Kamisawa T.
        • et al.
        Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas.
        Pancreatology. 2017; 17: 738-753
        • Chiaro M. Del
        • Besselink M.G.
        • Scholten L.
        • et al.
        European evidence-based guidelines on pancreatic cystic neoplasms.
        Gut. 2018; 67: 789-804
        • Charlson M.E.
        • Pompei P.
        • Ales K.L.
        • et al.
        A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
        J Chronic Dis. 1987; 40: 373-383
        • Dindo D.
        • Demartines N.
        • Clavien P.A.
        Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey.
        Ann Surg. 2004; 240: 205-213
        • Bassi C.
        • Dervenis C.
        • Butturini G.
        • et al.
        Postoperative pancreatic fistula: an international study group (ISGPF) definition.
        Surgery. 2005; 138: 8-13
        • Bassi C.
        • Marchegiani G.
        • Dervenis C.
        • et al.
        The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after.
        Surgery. 2017; 161: 584-591
        • Wente M.N.
        • Bassi C.
        • Dervenis C.
        • et al.
        Delayed gastric emptying (DGE) after pancreatic surgery: A suggested definition by the International Study Group of Pancreatic Surgery (ISGPS).
        Surgery. 2007; 142: 761-768
        • Wente M.N.
        • Veit J.A.
        • Bassi C.
        • et al.
        Postpancreatectomy hemorrhage (PPH)-An International Study Group of Pancreatic Surgery (ISGPS) definition.
        Surgery. 2007; 142: 20-25
        • Bosman F.
        • Carneiro F.
        • Hruban R.
        • et al.
        WHO Classification of Tumors of Digestive System.
        WHO Press, 2010
        • From R.
        • Baltimore T.H.E.
        • For M.
        • et al.
        Meeting for neoplastic precursor lesions in the.
        . 2016; 39: 1730-1741
        • Pezzilli R.
        • Capurso G.
        • Falconi M.
        • et al.
        The applicability of a checklist for the diagnosis and treatment of exocrine pancreatic insufficiency: results of the Italian Exocrine Pancreatic Insufficiency Registry.
        Pancreas. 2020; 49: 793-798
        • Klibansky D.A.
        • Reid-Lombardo K.M.
        • Gordon S.R.
        • et al.
        The clinical relevance of the increasing incidence of intraductal papillary mucinous neoplasm.
        Clin Gastroenterol Hepatol. 2012; 10: 555-558
        • Crippa S.
        • Fogliati A.
        • Valente R.
        • et al.
        A tug-of-war in intraductal papillary mucinous neoplasms management: comparison between 2017 International and 2018 European guidelines.
        Dig. Liver Dis. 2021; 53: 998-1003
        • Crippa S.
        • Pergolini I.
        • Rubini C.
        • et al.
        Risk of misdiagnosis and overtreatment in patients with main pancreatic duct dilatation and suspected combined/main-duct intraductal papillary mucinous neoplasms.
        Surgery. 2016; 159: 1041-1049
        • Cauley C.E.
        • Waters J.A.
        • Dumas R.P.
        • et al.
        Outcomes of Primary Surveillance for Intraductal Papillary Mucinous Neoplasm.
        J Gastrointest Surg. 2012; 16: 258-266
        • Chhoda A.
        • Yousaf M.N.
        • Madhani K.
        • et al.
        Comorbidities drive the majority of overall mortality in low-risk mucinous pancreatic cysts under surveillance.
        Clin Gastroenterol Hepatol. 2020; : 1-11
        • Vanella G.
        • Crippa S.
        • Archibugi L.
        • et al.
        Meta-analysis of mortality in patients with high-risk intraductal papillary mucinous neoplasms under observation.
        Br J Surg. 2018; 105: 328-338
        • Crippa S.
        • Bassi C.
        • Salvia R.
        • et al.
        Low progression of intraductal papillary mucinous neoplasms with worrisome features and high-risk stigmata undergoing non-operative management: a mid-term follow-up analysis.
        Gut. 2017; 66: 495-506
        • Sánchez-Velázquez P.
        • Muller X.
        • Malleo G.
        • et al.
        Benchmarks in pancreatic surgery: a novel tool for unbiased outcome comparisons.
        Ann. Surg. 2019; 270: 211-218
        • Andreasi
        • Partelli
        • Capurso
        • et al.
        Long-term pancreatic functional impairment after surgery for neuroendocrine neoplasms.
        J. Clin. Med. 2019; 8: 1611
        • Wu L.
        • Nahm C.B.
        • Jamieson N.B.
        • et al.
        Risk factors for development of diabetes mellitus (Type 3c) after partial pancreatectomy: a systematic review.
        Clin Endocrinol (Oxf). 2020; 92: 396-406
        • Phillips M.E.
        Pancreatic exocrine insufficiency following pancreatic resection.
        Pancreatology. 2015; 15: 449-455
        • Halloran C.M.
        • Cox T.F.
        • Chauhan S.
        • et al.
        Partial pancreatic resection for pancreatic malignancy is associated with sustained pancreatic exocrine failure and reduced quality of life: a prospective study.
        Pancreatology. 2011; 11: 535-545
        • Moore J.V.
        • Tom S.
        • Scoggins C.R.
        • et al.
        Exocrine pancreatic insufficiency after pancreatectomy for malignancy: systematic review and optimal management recommendations.
        J Gastrointest Surg. 2021; 25: 2317-2327
        • Lim P.W.
        • Dinh K.H.
        • Sullivan M.
        • et al.
        Thirty-day outcomes underestimate endocrine and exocrine insufficiency after pancreatic resection.
        HPB. 2016; 18: 360-366
        • Miyasaka Y.
        • Ohtsuka T.
        • Tamura K.
        • et al.
        Predictive factors for the metachronous development of high-risk lesions in the remnant pancreas after partial pancreatectomy for intraductal papillary mucinous neoplasm.
        Ann Surg. 2016; 263: 1180-1187
        • Kang M.J.
        • Jang J.-Y.
        • Lee K.B.
        • et al.
        Long-term prospective cohort study of patients undergoing pancreatectomy for intraductal papillary mucinous neoplasm of the pancreas.
        Ann Surg. 2014; 260: 356-363
        • He J.
        • Cameron J.L.
        • Ahuja N.
        • et al.
        Is it necessary to follow patients after resection of a benign pancreatic intraductal papillary mucinous neoplasm?.
        J Am Coll Surg. 2013; 216: 657-665
        • Müller M.W.
        • Friess H.
        • Kleeff J.
        • et al.
        Is there still a role for total pancreatectomy?.
        Ann Surg. 2007; 246: 966-974
        • Chiaro M. Del
        • Rangelova E.
        • Segersvärd R.
        • et al.
        Are there still indications for total pancreatectomy?.
        Updates Surg. 2016; 68: 257-263
        • Palmeri M.
        • Franco G. Di
        • Bianchini M.
        • et al.
        Prognostic impact of conservative surgery for pancreatic IPMNs.
        Surg Oncol. 2021; 38101582
        • Sauvanet A.
        • Gaujoux S.
        • Blanc B.
        • et al.
        Parenchyma-sparing pancreatectomy for presumed noninvasive intraductal papillary mucinous neoplasms of the pancreas.
        Ann Surg. 2014; 260: 364-371